Development of OP-1250.
In the Clinic
Our investigational drug, OP-1250, is an estrogen receptor antagonist. It was developed to compete with estrogen for binding to the receptor and keep it in a completely inactive state.
OP-1250 is currently in Phase 1/2 development as a single-agent treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+, HER2- MBC).
Target Patient Population
Metastatic Breast Cancer
ER+, HER2- MBC (with and without CNS metastases)
ER+, HER2- MBC(1) (combination with CDK4/6i)(1)
ER+, HER2- MBC with PIK3CA mutated (combination with PIK3αi)(1)
ER+ with ESR1 mutation(1)
HER2+ Metastatic Breast Cancer with CNS mets
ER+, HER2+ MBC with CNS metastases
Gynecology — Oncology